secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2023-04-05T23:59:59+00:00
Accession:  0001798749-23-000023
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aerovate Therapeutics enters into $75M ATM equity offering with BofA Securities
-------------------------------------------------------------------------------

- Entered into ATM Sales Agreement with BofA Securities to sell up to $75M of common stock.
- Shares sold at market prices; BofA receives 3% commission on gross proceeds.
- Company not obligated to sell any shares; may suspend or terminate offering at any time.
- Offering made under existing effective shelf registration statement on Form S-3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000179874923000023/0001798749-23-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000179874923000023/tmb-20230405x8k.htm
  HTML page:      https://secwatch.observer/filing/0001798749-23-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer